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circulation, and became widely used as a valuable tool to combat acute rejection episodes (Ortho Multicenter Transplant Study Group, 1985; Ponticelli et al., 1987) . Nevertheless, these monoclonal formulations still maintained some of the similar side effect profile of the polyclonal formulations, including cytokine release syndrome and human antigenic response to animal proteins, which lead to limited dosing in some patients (Jaffers et al., 1986) . The 1980's marked an important era in transplantation with new advances in genetic engineering. Monoclonal antibodies became more sophisticated, targeting specific T cell populations and allowing blockade of T cell activation, such as the interleukin-2 receptor (IL-2R) or CD25 (Vincenti et al., 1997) . Moreover, the ability to avoid antigenic proteins by encoding genetic sequences of DNA binding sites of animal proteins onto human antibodies led to the development of chimeric monoclonal antibodies (Boulianne et al., 1984; Jones et al., 1986; Morrison et al., 1984) . Using these techniques, soluble fusion proteins can be formed by merging nonantibody receptors with the Fc portion of antibodies.
Antibodies
Comprehension of the structure and function of antibodies is critical to understanding the efficacy of antibody induction therapy. Antibodies are composed of two identical heavy chains (either µ, , , , or ) and two identical light chains (either or ). The heavy and light chain portions create two identical antigen binding sites (Fab fragment) which are held together by the common region, termed the Fc portion (Capra & Edmundson, 1977) . The type of heavy chain differentiates the immunoglobulin type as IgM, IgG, IgA, IgE, and IgD. In clinical transplantation, the IgG molecule is typically utilized, as it's readily produced and structurally feasible to manipulate with ease ( Fig. 1) . (Tite et al., 1986; Wong et al., 1990) . In some instances, antibody binding can lead to both activation and inhibition by inducing surface molecule internalization, whereby the molecule is removed from the surface of the cell (Kerr & Atkins, 1989) . This results in a negligible net effect. A major limitation of antibody use is the inability to directly bind intracellular molecules. Antibodies have the ability to deplete target cells through two fundamental mechanisms. First, antibodies have the capability to activate the complement system resulting in complement-mediated lysis of target cells. Second, certain cells with Fc region receptors have the ability to phagocytose cells covered with antibodies through a mechanism termed antibody-dependent cellular cytotoxicity (ADCC) (Fig.2) . The efficacy with which this occurs depends upon the Fab fragment and the Fc region (Ferrant et al., 2004) . It is important to note that cells which have significantly matured, or memory cells, are somewhat resistant to antibody-dependent depletion mechanisms, possibly due to increased expression of antiapoptotic or complement regulatory genes (Pearl et al, 2005) . The vast properties of antibodies make them suitable for therapeutic indications. Nevertheless, even minor changes in antibody structure can significantly alter function. Additionally, the interplay of the complement system and ADCC properties further complicates the predicted function of various antibody-depleting therapies. Fig. 2 . Antibody-dependent cellular cytotoxicity (ADCC). The Fc receptor on the machrophage is used to bind the constant Fc portion of antibodies to facilitate engulfment of cells coated with antibodies
Clinical classification of induction agents
Induction immunosuppressive medications can be classified into two groups: depleting agents and non-depleting agents. The categorization is based on the ability of the medication to target specific antigens or cells, leading to a decrease in the total expression or cell count. Most depleting agents are relatively potent with potential for toxicity with prolonged administration. Non-depleting agents are generally well-tolerated. Depleting agents are also used for severe or refractory cases of acute rejection and have proven to be more effective than glucocorticoids in treating episodes of acute rejection (Webster et al., 2006) . In addition, the use of induction agents has decreased the rates of acute rejection in the first 6 months compared to no induction therapy (Szczech et al., 1997) . Although these short-term benefits appear promising, long-term outcomes, including patient and graft survival rates, have not been shown to be altered by the use of induction therapy. This is possibly related to the effects of long-term maintenance immunosuppressive therapy or patient co-morbidities. The overall success of a transplanted renal allograft is contingent on both surgical prowess and the use of potent immunosuppressive medications. Although induction therapy has not affected surgical morbidity, the rate of allograft thrombosis has been shown to be reduced in children with the use of induction agents (Humar et al., 2001; Singh et al., 1997) . However, not all medications used are FDA-approved for induction therapy. Moreover, it is important to note that these medications are not without definite risks, including serious infectious complications and the development of post-transplant lymphoproliferative disorder (PTLD), which has been well-described with the use of OKT3 and maintenance immunosuppression (Bustami et al., 2004; Jamil et al., 1999) . Because of the effects of depleting agents on T cells, appropriate prophylactic therapies should be administered to all transplant recipients. Duration of therapy is typically contingent on the donor and recipient immunological history. Thus, tailoring the immunosuppressive regimen to each patient is critical to avoiding complications. In 1995 induction therapy was used in less than half of all kidney transplants in the United States, while 10 years later, approximately 70% of all kidney transplant recipients received induction therapy (Meier-Kriesche et al., 2006) . Given the availability of various potent, specific induction agents in modern transplantation, the clinical dilemma lies in selecting the most appropriate agent for a given patient, taking into account co-morbidities, donor quality, immunological status, and planned maintenance therapy.
Depleting agents
2.1 Antithymocyte globulin 2.1.1 Mechanism Various polyclonal depleting agents are available; however, this discussion will focus on rabbit antithymocyte globulin (rATG). In rATG, the polyclonal heterologous antibody formulation is produced from immunizing rabbits with human thymocytes, which serve as the immunogens (Fig. 3) (Hardinger, 2006) . The rabbit serum is then gathered and purified to remove antibodies with potentially detrimental effects and only the IgG isotypes are collected. Despite these purification techniques, it is possible that the majority of antibodies in these formulations serve no therapeutic purpose (Bonnefoy-Berard et al., 1991) . When administered to humans, the rATG antibody formulations bind all antigens that the rabbits were exposed to during the immunization process. Rabbit ATG binds multiple T cell surface antigens and receptors involved in antigen recognition, adhesion and costimulation. These include CD2, CD3, CD4, CD5, CD8, CD28, CD45, and CD40L. In addition, rATG may also bind non-T cell molecules such as CD16, CD20, CD56, and the major histocompatibility molecules (class I and II) (Bonnefoy-Berard et al., 1991; Hardinger, 2006) . The depleting effect of rATG occurs within 24 hours of administration and can persist with a prolonged serum half-life of several weeks (Bunn et Guttmann et al., 1997) . The effects of lymphocyte depletion are persists for years following administration, as evidenced by selectively low CD4 + T cell counts (Brennan et al., 1999; Hardinger et al., 2004) . 
Applications
Rabbit ATG has been approved for use as an induction agent and for the treatment of acute rejection in Europe since 1984 (IMTIX-SangStat, 2003) . However, in the United States, rATG is indicated only for the treatment of acute rejection (as of 1998). Nevertheless, it is routinely administered as induction therapy in many centers in the United States. Early studies demonstrated an increased risk of infectious complications and post-transplant malignancy when administered in conjunction with cyclosporine (Merion et al., 1984) . With a better understanding of PTLD, improved infectious prophylaxis protocols, and experience using lower doses of rATG, the use of rATG as an induction agent has increased. The most effective use of rATG depends on timing of administration. Ideally, the first dose should be given before the vascular anastomosis at the time of transplantation (typical dose 1.5mg/kg/dose for a total of 4.5 to 7.5 mg/kg). This may minimize ischemia-reperfusion injury and potentially prevent the development of delayed graft function (Shoskes & Halloran, 1996) . Delayed graft function is known to portend poorer outcomes in kidney transplant recipients, thus rATG has been used in patients at higher risk of developing this delayed graft function, including recipients of donation after cardiac death donors, and recipients of extended criteria donors (Beiras-Fernandez et al., 2006; Cecka et al., 1993; Shield et al., 1997) . It is also administered in patients at higher risk of developing acute rejection in the perioperative period, such as retransplants and patients who may have prolonged avoidance of calcineurin inhibitors as well as to minimize maintenance therapies such as facilitating early corticosteroid withdrawl (Schaffer et al., 2003; Shield et al., 1997) .
The use of rATG to treat severe or refractory acute cellular rejection episodes has been wellestablished. Refractory acute cellular rejection is defined as failure to respond to 3 consecutive days of bolus methylprednisolone (i.e. 500 mg per day) treatment. rATG is superior to glucocorticoids in treating acute cellular rejection episodes. Compared to other polyclonal antibody formulations, rATG has proven to be superior in reversing steroidresistant rejection and prolonging rejection-free events (Gaber et al., 1998) . Patient or graft survival, however, have not been shown to be affected. Given the potency of rATG, it is typically used as supplemental agent to corticosteroids for the treatment of severe or refractory episodes of acute rejection. Additionally, recurrent episodes of acute rejection may be treated with multiple courses of rATG as long as preformed antirabbit antibodies are not present (Bock et al., 1995) .
Adverse effects
Patients treated with rATG may experience a variety of side effects. It has been associated with a phenomenon called cytokine release syndrome (Fig. 4) , which is common to many polyclonal antibody formulations. Patients may experience mild flu-like symptoms, such as fever, chills, nausea, urticaria, rash, and headache (Guttmann et al., 1997) . This occurs as a result of increased production of tumor necrosis factor-, IL-1, and IL-6 from antibody binding to cell surface receptors and ensuing cell lysis (Debets et al., 1989; Guttmann et al., 1997; Hardinger, 2006) . Premedication with corticosteroids, antipyretics, and antihistamines can prevent and/or treat the flu-like symptoms that can occur in a subset of kidney transplant recipients. In some cases, patients may develop more severe shock-like reactions, such as dyspnea, severe hypotension, pulmonary edema, or even anaphylaxis. Although patients frequently experience the mild flu-like symptoms and not the more severe reactions, recipient co-morbid conditions, such as cardiac or pulmonary disease, should be considered when selecting rATG as an induction agent. Serum sickness has also been associated with rATG administration in up to 7-10% of patients (Buchler et al., 2003; Mourad et al., 2001) . 
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Hematological adverse events may occur, including leucopenia and thrombocytopenia. It is important to monitor white blood cell, lymphocyte, and platelet counts for patients receiving rATG. Not surprisingly, these events may lead to an increase in infectious complications, including cytomegalovirus (CMV), herpes simplex virus, Epstein-Barr virus (EBV), and varicella (Abott et al., 2002; Gourishankar et al., 2004) .
Muromonab (OKT3) 2.2.1 Mechanism
Muromonab, or OKT3, is a monoclonal antibody. It is an IgG2 mouse antibody known to bind the epsilon component of human CD3. The CD3 complex is a T cell receptor intimately involved in T cell signaling and activation via a calcineurin-dependent pathway (Ortho Multicenter Transplant Study Group, 1985) . Once the antibody binds the target cell, complement is activated leading to cell lysis and ADCC (Vallhonrat et al., 1999) . By this method, most T cells are effectively removed from the peripheral circulation. However, the T cell binding also results in T cell activation before clearance, leading to systemic cytokine release. When OKT3 binds the T cell receptor, the CD3 complex is internalized ( Fig. 5 ) to prevent further activation by persistent antigen presence (Chatenoud et al., 1990) . Effectively, T cells that fail to be cleared are unable to be activated by the CD3 complex. 
Applications
Early studies demonstrated the efficacy of OKT3 as an induction agent in kidney transplantation in conjunction with maintenance immunosuppression (Debure et al., 1988; Norman et al., 1988; Vigeral et al., 1986) . Efficacy relies on serum availability, thus once administration of OKT3 ceases, maintenance immunosuppressive therapy is required. Typical dosing is 5 to 10 mg/dose through a peripheral or central line. Premedication with methylprednisolone, acetaminophen, and diphenhydramine can significantly lower the amount of cytokine release associated with first infusion (Chatenoud et al., 1991) . Additionally, slower administration rates are helpful in blunting the cytokine response. Dosing can be continued for up to 14 days for a total dose of 70 mg. Patients with 364 significant sensitization have especially benefitted from OKT3 (Opelz, 1995) . In addition, recipients of renal allografts experiencing delayed graft function benefit from OKT3 infusion, as calcineurin inhibitor therapy can be delayed, avoiding added renal toxicity (Benvenisty et al., 1990) . Early studies of OKT3 demonstrated a reduction in acute rejection rates and time to first rejection episodes; however, overall patient and graft survival rates were not changed (Henry et al., 2001; Norman et al., 1993) . Its use has been linked to various infectious and malignant morbidities. Aseptic meningitis has also been linked to its use (Martin et al., 2002) . Moreover, PTLD rates are significantly increased, especially in EBV negative recipients receiving EBV positive allografts (Thistlethwaite et al., 1988; Cherikh et al., 2003) . The significant side effect profile and immunogenicity of OKT3 has lead to a decline in its use as an induction agent. OKT3 remains an effective treatment for severe episodes of acute cellular rejection, or those refractory to steroid therapy and rATG. In the majority of cases of vigorous rejection, OKT3 has proven efficacious (Cosimi et al., 1981b; Ortho Multicenter Transplant Study Group, 1985; Thistlethwaite et al., 1987) . The efficacy of OKT3 is maintained even if prior lymphocyte depleting agents have been used (Ponticelli et al., 1987) . However, timing of therapy is important, as a delay in treatment following the 3 days of high-dose methylprednisolone therapy for steroid-resistant acute rejection is associated with decreased success (Tesi et al., 1993) . OKT3 has also been used to treat vascular rejection episodes (Banff grade 2 or 3) (Kamath et al., 1997) .
Adverse effects
As a monoclonal antibody, OKT3 selectively targets T cells, avoiding the leucopenia and thrombocytopenia associated with rATG. Similar to rATG, OKT3 is associated with cytokine release syndrome. With respect to OKT3, this is more pronounced, especially with the first dose as the T cells may be in a more activated state (i.e. acute cellular rejection). The cytokine release syndrome with OKT3 results in severe flu-like symptoms, including fever, chills, malaise, nausea, vomiting, and even rigors (Thistlethwaite et al., 1988) . As vascular permeability increases, patients may experience pulmonary edema, hypotension, and volume overload. If there is renal dysfunction present, patients should undergo hemodialysis prior to first infusion to avoid volume-related complications. Patients should be closely monitored, especially during the initial infusions for cardiac or pulmonary complications. The utilization of OKT3 is clearly associated with antimouse antibodies in at least 30% of patients, depending on the immunosuppression regimens used at the time (Colvin & Preffer, 1991; Schroeder et al., 1990) . The antibodies form against the mouse IgG molecule. If there is antibody formation, OKT3 is typically not reused, although higher doses may overcome this. This can be documented by laboratory evidence of antimouse antibody Legendre et al., 1992) .
Alemtuzumab 2.3.1 Mechanism
Alemtuzumab, or Campath-1H, is a monoclonal antibody to rat antihuman CD52 (Fig. 6) . It is an IgG1 humanized molecule (Hale et al., 1986) . CD52 is present in high abundance on most lymphocytes, including T cell, B cells, and monocytes, but not hematopoietic precursors (Hale, 2001 ). It effectively depletes T cells, and some B cells and monocytes in the circulation as well as the allograft (Kirk et al., 2003) . 
Applications
Alemtuzumab has not been approved for use as an induction agent; however, this is a common off-label use. Currently, it is only approved to treat lymphogenous malignancies. As an off-label induction agent, it's been used with various immunosuppression regimens, including steroid-sparing regimens. Effectively, it depletes lymphocytes at the time of transplantation and last for several months to a year before the immune system is reconstituted (Gabardi et al., 2011) . Alemtuzumab is given at a dose of 30 mg or 0.3 mg/kg through a peripheral line over 3 hours. Sometimes 2 doses are given, although T cells are expectedly removed within 1 hour of initial administration (Kirk et al., 2003; Pearl et al., 2005) . Alemtuzumab depletes all T cell subsets, but has a predilection for more naïve T cells (Pearl et al., 2005) . Memory T cell subsets may not be depleted with this therapy, but these cell types are especially susceptible to calcineurin inhibitors. Because of the prompt and intense depletion, alemtuzumab is especially appealing to use in patients with delayed graft function, as calcineurin inhibitor therapy can be withheld to avoid concomitant calcineurininduced renal insults. Early studies of alemtuzumab demonstrated its efficacy as a treatment therapy for acute rejection; however, it was associated with significant infectious morbidity and mortality (Hale et al., 1986) . Patients were significantly over-immunosuppressed, especially on a triple maintenance therapy. More recent literature has been small studies or anecdotal data (Clatworthy et al., 2009; Csapo et al., 2005; Jirasiritham et al., 2010) . Because its efficacy is greatest against naïve T cells, its use in sensitized patients may-be limited. In a recent study, alemtuzumab was prospectively compared to basiliximab and rATG as an induction agent in patients on a steroid-sparing immunosuppressive regimen (Hanaway et al., 2011) . Alemtuzumab demonstrated lower short-term rates of acute rejection compared to basiliximab in patients at low-risk of developing acute rejection. At 3-years, however, the rates of acute rejection were no different between alemtuzumab and rATG. Additionally, patients receiving alemtuzumab did not experience an increased incidence of adverse events.
Adverse effects
Similar to other depleting agents (rATG and OKT3), alemtuzumab is also associated with cytokine release syndrome, albeit to a lesser extent. If properly premedicated with methylprednisolone, acetaminophen, and diphenhydramine, the cytokine release is blunted. Urticaria and rash manifestations are common, while anaphylaxis and hypotension have also been reported. It has not been associated with antibody formation, as in the case of OKT3. It has been linked to the development of autoimmune thyroiditis in patients treated with alemtuzumab for multiple sclerosis (Coles et al., 1999) . This has also been reported in a renal transplant recipient treated with alemetuzumab (Kirk et al., 2006) .
Non-depleting agents

Basiliximab 3.1.1 Mechanism
Basiliximab is a chimeric mouse-human monoclonal IgG1 antibody to CD25. CD25 is thesubunit of the IL-2 receptor, which is a binding site of IL-2. Basiliximab inhibition of IL-2 binding occurs through steric hindrance (Fig.7) . In this case, the effect is not depletional, but rather, preventative of early T cell activation (Gabardi et al., 2011) . 
Applications
Basiliximab's biological bias for naïve T cells has limited its role to an induction agent. One dose is typically administered on the day of transplant as well as one dose on postoperative day 4 (20 mg per dose) through a peripheral line. Its use has been associated with decreased rates of acute cellular rejection compared to no formal induction agent (besides methylprednisolone) on triple or double drug immunosuppression regimens (Kahan et al., 1999; Nashan et al., 1997) . Additional studies comparing basiliximab induction to polyclonal antibody depleting induction agents in the setting of triple maintenance immunosuppression regimens have shown similar outcomes, including acute rejection rates and delayed graft function (Lebranchu et al., 2002; Mourad et al., 2004) . Basiliximab induction has also been used in steroid avoidance immunosuppression regimens (Afaneh et al., 2010) . In the setting of monotherapy or calcineurin inhibitor free regimens, basiliximab has not been shown to be useful (Parrott et al., 2005; Vincenti et al., 2001) . In some instances of excellent allograft human leukocyte antigen (HLA)-matching (i.e. 2-haplotype matches), it's been used as an effective induction agent with steroid-sparing immunosuppressive regimens (Afaneh et al., 2010) . Given the relatively mild side effect profile, basiliximab is well-tolerated in all patients, even those with significant cardiac or pulmonary co-morbidities. It has no role in the treatment of acute rejection episodes as a rescue agent.
Adverse effects
Because of the mechanism of action of basiliximab, the side effect profile is relatively mild (Kahan et al., 1999; Nashan et al., 1997) . Cytokine release syndrome does not occur, as T cells are not activated or stimulated. The most serious adverse event is hypersensitivity, which is rare (<1%) (Gabardi et al., 2011) . There is no increased risk of infectious complications or PTLD compared to no induction therapy (Cherikh et al., 2003) .
Daclizumab 3.2.1 Mechanism
Similar to basiliximab, daclizumab is an antagonist to CD25; however, it is a humanized IgG1 antibody. The CD25 molecule was the first humanized monoclonal antibody to be successfully targeted in the field of transplantation (Kirkman et al., 1991) . The mechanism of action of daclizumab essentially duplicates that of other IL-2 receptor antagonists.
Applications
Like basiliximab, daclizumab has been shown to decrease the incidence of acute cellular rejection when administered as an induction agent (Hershberger et al., 2005; Nashan et al., 1999) . Given the favorable side effect profile, it is tolerated well in recipients, irrespective of co-morbid conditions. The main disadvantage of daclizumab, as compared to basiliximab, is that it is more costly and requires repeated administrations (Gabardi et al., 2011) . Because the demand for the medication has been relatively low, it has been discontinued by the manufacturer. It has no role as a rescue agent for acute rejection.
Adverse effects
The side effect profile is similar to that of basiliximab and generally favorable. Cytokine release is not typically associated with this agent (Hershberger et al., 2005; Nashan et al., 1999) . Like other IL-2 receptor antagonists, the risk of PTLD is not significantly increased with use (Cherikh et al., 2003) .
Desensitizing agents
Rituximab 4.1.1 Mechanism
Rituximab is a monoclonal chimeric antibody to the CD20 molecule. CD20 is a glycoprotein on the cell surface of circulating, mature B cells. Rituximab effectively depletes CD20 + cells from the circulation by inducing apoptosis (Deans et al., 2002) . These cells are precursors to antibody-producing plasma cells, and their role in transplantation is only partially characterized. They may play a role in acute rejection, as B cells can act as antigenpresenting cells.
Applications
Rituximab is approved for use in various lymphomas, leukemias, PTLD, and rheumatoid arthritis (Gabardi et al., 2011; Grillo-Lopez et al., 1999) . Peripheral veins can be used for administration and dosing is dependent on the indication. A recent study examining the role of rituximab as an induction agent found no benefit compared to placebo (Tyden et al., 2009 ). However, it does play a role as a desensitizing agent in patients with preformed donor specific antibodies (DSA), in conjunction with total plasmapheresis and/or intravenous immunoglobulin (IVIG) (Fuchinoue et al., 2011; Sonnenday et al., 2004) . Additionally, it has been used to aid in transplanting across blood group barriers in donor recipient pairs and in patients with positive crossmatches following antibody elimination. Rituximab is increasingly being used to treat episodes of vascular rejection and antibodymediated rejections (Y.T. Becker et al., 2006; Fehr et al., 2009) . Finally, rituximab is a proven and effective agent in the treatment of PTLD (Svoboda et al., 2006) . Administration does not replace immunosuppression reduction or chemotherapy, but rather supplements the other modalities.
Adverse effects
Rituximab is generally well-tolerated with minimal side effects. Anaphylaxis remains a theoretical concern, as is the case with most agents. Reports on infectious complications related to rituximab have been variable (Grim et al., 2007; Kamar et al., 2010; Nishida et al., 2009 ). In some instances there was no difference in bacterial, viral, or fungal infections in kidney transplant recipients treated with rituximab, however, this remains controversial.
Bortezomib 4.2.1 Mechanism
Bortezomib is a proteasomal inhibitor that causes apoptosis of plasma cells. It binds the 26S subunit of the proteasome (Bonvini et al., 2007) . Proteasome inhibition ultimately leads to apoptosis during mitosis. Bortezomib selectively causes apoptosis in CD138 + plasma cells (Perry et al., 2009 ). Additionally, Bortezomib may block T cell cycling and decrease the number of circulating B cells by reducing bone marrow levels of IL-6 (San Miguel et al., 2008) .
Applications
Bortezomib has not been approved for use in kidney transplantation; however, it has been used in sensitized patients (Perry et al., 2009) . Bortezomib has been successfully used to decrease DSA levels, which may play a role in acute antibody-mediated rejection (AMR) (Trivedi et al., 2009) . Furthermore, in vivo data has demonstrated a decrease in the percentage of bone marrow plasma cells, antibody production, and allospecificities of plasma cells in bone marrow aspirates of patients treated with bortezomib i in the setting of AMR (Perry et al., 2009 ).
Adverse events
Bortezomib has been associated with various side effects. Although gastrointestinal side effects are the most common, peripheral neuropathy has also been reported, especially in patients with a pre-existing history of neuropathy (Bonvini et al., 2007) . Moreover, myelosuppression and shingles has been reported.
Intravenous Immunoglobulin (IVIG) 4.3.1 Mechanism
Intravenous immunoglobulin, or IVIG, is pooled polyclonal antibodies from different human donors. These are high-dose human IgG fractions with a wide range of specificities. These are non-T cell specific formulations and have no specific cell targets (Jordan et al., 2011) . It is able to bind activated complement components or even inhibit complement activation (Jordan et al., 2009) . IVIG may also modulate the alloimmune response by binding to the Fc receptor of antigen-presenting cells, effectively quelling the alloimmune response (Kazatchkine & Kaveri, 2001 ).
Applications
Despite the inability to deplete T cells, IVIG is an effective treatment of acute cellular rejection. Early studies showed that IVIG was as effective as OKT3 in reversing steroidresistant acute rejection episodes (Casadei et al., 2001 ). In the setting of antibody-mediated rejection, IVIG has been shown to be beneficial when used in conjunction with plasmapheresis and/or rituximab (Lefaucher et al., 2009; Shehata et al., 2010) . As a desensitization agent alone, no study has demonstrated a clear benefit (Pisani et al., 1999; Shehata et al., 2010) . Definitive reduction of antibody was not shown and a survival advantage was not evident.
Adverse effects
The side-effect profile of IVIG increases with dosing. High-dose IVIG is associated with more infusion-related complications, such as headache, thrombotic incidents, hemolysis, bronchospasms, osmotic nephropathy, or even aseptic meningitis (Jordan et al., 2011; Kahwaji et al., 2009) . Sucrose-based and high osmolality products have a higher risk of developing osmotic nephropathy as opposed to other preparation. Nevertheless, it is typically well-tolerated, especially at lower doses and most patients report only headache.
Experimental agents
Siplizumab (MEDI-507)
Originally described as BTI-322, siplizumab is a monoclonal humanized antibody to CD2. It is an IgG1k molecule derived from rat (Pruett et al., 2009) . CD2, or lymphocyte functionassociated antigen-2 (LFA-2), is an important T cell adhesion molecule that binds to CD58, or LFA-3. This is a transmembrane signal transduction molecule that facilitates T cell receptor binding. Early studies examined the use of siplizumab as an induction agent and treatment modality for acute rejection in solid organ transplantation as well as graft-versushost disease (Pruett et al., 2009; Squifflet et al., 1997) . The first human study of siplizumab demonstrated the safety and feasibility in kidney transplantation, as compared to placebo; however, current endeavors are focused on investigating its use in nonmyeloablative conditioning regimens to achieve mixed chimerism (Kawai et al., 2008; Pruett et al., 2009; Spitzer et al., 2003) . In addition, it is being investigated for the treatment of plaque psoriasis (Langley et al., 2010) .
Alefacept
Alefaept is a dimeric fusion protein (Fig.8) constituted from LFA-3 and the human Fc portion of IgG1. Studies have demonstrated inhibition of T cell proliferation and depletion of effector memory T cells (Ellis & Krueger, 2001; Gordon et al., 2003) . Currently, alefacept is approved to treat plaque psoriasis. Preclinical studies in nonhuman primates have demonstrated a survival benefit of alefacept, when used in conjunction with costimulatory blockade, but not alone; however in human trials have never shown a benefit (Weaver et al., 2009) . Fig. 8 . Mimicry. In this figure, the antibody is fused with a protein structural similar to the intended antigen, which can serve as activating or inhibitory
Costimulatory blockade 5.3.1 Abatacept
Abatacept is a recombinant cytotoxic T-lymphocyte antigen 4 (CTLA4) fused with the Fc portion of IgG1 (Lenschow et al., 1992; Turka et al., 1992) . Animal models demonstrated its ability to delay or even prevent the onset of allograft rejection, which is comparable to basiliximab and some polyclonal antibody therapies (Kirk et al., 1997; Lenschow et al., 1992; Turka et al., 1992) . It has been approved for treatment of rheumatoid arthiritis (Genovese et al., 2005; Nogid & Pham, 2006) . Further investigations of this medication are not currently under development.
Belatacept
Belatacept is the improved version of abatacept, providing selective blockade of T cell activation as a fusion protein. Two amino acids have been changed to improve dissociation rates when binding to CD80 and CD86 (Vincenti et al., 2005 (Vincenti et al., , 2010 . In the phase II trial comparing belatacept to cyclosporine, acute rejection rates were similar, while allograft function was significantly improved in patients receiving belatacept (Vincenti et al., 2005) . In the phase III trial of kidney transplantation, patients receiving belatacept experienced improved allograft function at 12 months; however, acute rejection rates and severity of acute rejection episodes were significantly higher in the belatacept arm of the study. Additionally, the incidence of PTLD was greater in patients receiving belatacept (Vincenti et al., 2010 ). An additional study investigating the efficacy of belatacept in kidney transplantation of extended criteria donors demonstrated similar results, with a predilection towards central nervous system (CNS) forms of PTLD (Durrbach et al., 2010) . The novelty of costimulation blockade is the ability to avoid calcineurin inhibitors, especially in allografts at increased risk of delayed graft function. Belatacept has recently been approved for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids (Bristol-Myers Squibb Company 2011) . Current recommendations include using it only in patients who are EBV seropositive; however, patients should be monitored for an increased risk of infectious complications and Progressive Multifocal Leukoencephalopathy.
CD7 antagonism
SDZCHH380 is a monoclonal antibody targeting CD7. This IgG1 chimeric mouse antibody was initially studied in kidney transplantation (Lazarovits et al., 1993; Sharma et al., 1997) . The CD7 molecule is expressed on T cells and natural killer cells during early differentiation, functioning as a costimulatory molecule. Early studies of SDZCHH380 as an induction agent in kidney transplantation demonstrated comparable short and long-term outcomes to OKT3 induction (Sharma et al., 1997) . Despite favorable results up to 4 years following administration, further investigative endeavors were not pursued in solid organ transplantation.
T cell receptor antagonism
T10B9, or Medi-500, is a monoclonal antibody to the T cell receptor. Specifically, this is a murine IgM molecule to the heterodimer region of the CD3 complex (Brown et al., 1996; Waid et al., 1992 Waid et al., , 2009 ). Because it does not bind directly to the Fc receptor, there is reduced immune stimulation and occurrence of cytokine release syndrome. The end result is T cell depletion. Early studies demonstrated the efficacy of this agent as induction therapy and a treatment modality for acute rejection in solid organ transplantation, as compared to OKT3 (Waid et al., 1997a (Waid et al., , 1997b . However, given the efficacy of similar humanized monoclonal antibodies, further investigations in solid organ transplantation were not pursued.
Special considerations
High risk donor kidneys & recipients
Marginal donor kidneys are defined as expanded criteria donors (ECD) or donation after cardiac death donors (DCD). These allografts are at higher risk of developing delayed graft function, which has been shown to decrease overall allograft survival and increase the incidence of acute rejection (Deroure et al., 2010; Rudich et al., 2002) . There was a large prospective, international, randomized controlled trial examining the efficacy of rATG versus basiliximab in patients at high risk of delayed graft function (Brennan et al., 2006) . Patients were maintained on a cyclosporine-based triple drug immunosuppression regimen and eligibility criteria included ECD or DCD allografts, standard criteria donors (SCD) with greater than 24 hours of cold ischemia time, repeat transplants, panel-reactive antibody value exceeding 20% before transplantation, donors with acute tubular necrosis (ATN), recipient black race, or one or more HLA mismatches. The incidence of delayed graft function was not significantly different between patients receiving rATG and basiliximab induction. However, the incidence of biopsy-proven acute rejection was significantly lower in patients receiving rATG. Additionally, severe rejection episodes requiring antibody therapy were less frequent in the rATG group. Interestingly, the overall incidence of infection was significantly lower in the basiliximab group, yet the incidence of CMV was lower in the rATG group.
Sensitization & incompatibility
Sensitization to HLA antigen typically occurs as a result of blood transfusions, pregnancy, or previous transplantation (Marfo et al., 2011) . These patients are more likely develop circulating DSA and have a positive cross-match during transplantation evaluation. Sensitized patients wait considerable longer on the deceased donor waitlist. Various modalities have been developed to combat sensitization. Antibodies can be removed by plasmapheresis and immunoadsorption techniques; however anti-HLA antibodies generally rebound and return to baseline (Hakim et al., 1990) . As discussed earlier, rituximab has also been used with varying success, as B cells recovery occurs 6 to 12 months following administration. Bortezomib has been used in sensitized patients (Perry et al., 2009) . Recently, a new medication called eculizumab has emerged as a humanized monoclonal antibody to complement component 5 (C5) to mediate complement-mediated injury, which may have potential in desensitization protocols (Larrea et al., 2010) . IVIG has also been used in sensitized patients to acutely decrease PRA levels, especially in ABOincompatible patients. Finally, splenectomy has also been used in desensitization protocols of ABO-incompatible patients (Kaplan et al., 2007) . Despite these numerous combinations of these therapies with acceptable short-term outcomes, intermediate-term outcomes have been modest at best. Some have reported graft survival rates at 3 years to be 78% (Haririan et al., 2009 ) and 4-year graft survival of only 66% (Lefaucher et al., 2007) . Additionally, higher rates of clinical and subclinical antibodymediated rejection have been reported (Haas et al, 2007; Loupy et al., 2009 ).
Older recipients
Several considerations should be examined when choosing induction therapy in older recipients. Older patients may have lower rates of acute rejection as a result of diminished immune activity (B.N. Becker 1996; Friedman et al., 2004) . There is also a higher rate of infectious complications as well as malignancies (Meier-Kriesche et al., 2001; Stratta et al., 2008) . Thus, less intense induction and immunosuppression appear sufficient. However, if significant HLA-mismatch is present, higher rates of acute rejection have been described (Frei et al., 2008; Fritsche et al., 2003; Giessing et al., 2003) . Nevertheless, the safety profile of IL-2 receptor antibodies in patients with considerable comorbidities, such as the older recipients, may be preferred.
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